CIK 0001094038
- Non-accelerated filer
- Smaller reporting company
Marker Therapeutics, Inc.
Sign in to watch- Ticker
- MRKR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 880277072
- Phone
- +1 713-400-6400
- Business address
- 2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE 1.311, HOUSTON, TX, 77021
- Former names
- TAPIMMUNE INC., TAPIMMUNE INC, GENEMAX CORP, EDUVERSE COM
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 58 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-16 | Makhzoumi Mohamad 10% owner | Purchase | +5,714,285 | $1.75 | $10.0M | 10,714,285 |
| 2021-03-16 | Florence Anthony A. Jr. 10% owner | Purchase | +5,714,285 | $1.75 | $10.0M | 10,714,285 |
| 2021-03-16 | Chang Carmen 10% owner | Purchase | +5,714,285 | $1.75 | $10.0M | 10,714,285 |
| 2021-03-16 | Behbahani Ali 10% owner | Purchase | +5,714,285 | $1.75 | $10.0M | 10,714,285 |
| 2021-03-16 | BASKETT FOREST 10% owner | Purchase | +5,714,285 | $1.75 | $10.0M | 10,714,285 |
| 2021-03-16 | New Enterprise Associates 16, L.P. 10% owner | Purchase | +5,714,285 | $1.75 | $10.0M | 10,714,285 |
| 2021-03-16 | Wilson John Robert Director | Purchase | +1,714,285 | $1.75 | $3.0M | 7,799,350 |
| 2021-03-16 | Vera Juan Chief Development Officer | Purchase | +571,428 | $1.75 | $1000K | 2,564,487 |
| 2021-03-16 | Hoang Peter L. President and CEO | Purchase | +142,857 | $1.75 | $250K | 332,568 |
| 2021-03-16 | ELMS STEVE Director | Purchase | +1,142,857 | $1.75 | $2.0M | 3,142,857 |
| 2021-02-11 | Hoang Peter L. President and CEO | Grant or award · Employee Stock Option (right to buy) | +430,000 | 430,000 | ||
| 2021-02-10 | Vera Juan Chief Development Officer | Grant or award · Employee Stock Option (right to buy) | +140,000 | 140,000 | ||
| 2021-02-10 | Szymanska Anna Vice President, Quality | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-02-10 | Loiacono Michael Chief Accounting Officer | Grant or award · Employee Stock Option (right to buy) | +140,000 | 140,000 | ||
| 2021-02-10 | Koneru Mythili Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +140,000 | 140,000 | ||
| 2021-02-10 | Kim Anthony H. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +160,000 | 160,000 | ||
| 2021-02-10 | Hoang Tsvetelina P VP, Research and Development | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-02-10 | Garrett Gerald Vice President, Clinical Ops. | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-02-10 | Agopyan Nadia VP, Regulatory Affairs | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2020-06-16 | Eastern Capital LTD 10% owner | Other disposition · Series E-1 Warrant | −416,667 | 0 |
Page 4 of 6 · 119 trades